GNH USA

Europe — EMA

Ovaleap (Follitropin Alfa (Genetical Recombination))

GNH USA supplies Ovaleap (Follitropin Alfa), a gonadotropin for controlled ovarian stimulation in assisted reproduction. Request a quote for global supply.

Follitropin Alfa (Genetical Recombination)

Request sourcing

1
Pack/s

What is Follitropin Alfa (Genetical Recombination)?

Follitropin alfa, the active ingredient in Ovaleap, is a gonadotropin presented as a sterile solution for subcutaneous injection use. It stimulates follicular development in women undergoing assisted reproductive techniques. GNH USA supplies Ovaleap as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

What is Follitropin Alfa (Genetical Recombination) used for?

Ovaleap is a recombinant follicle‑stimulating hormone used in the controlled ovarian stimulation pathway of assisted reproduction. - Anovulation (e.g., polycystic ovary syndrome): stimulates follicular growth to induce ovulation. - In vitro fertilisation (IVF) cycles: supports development of multiple follicles for egg retrieval. - Oocyte donation cycles: promotes follicular maturation in donor patients.

What are the side effects of Follitropin Alfa (Genetical Recombination)?

Common Side Effects: - Injection site reactions: redness, swelling, or mild pain at the injection site. - Mild ovarian hyperstimulation syndrome (OHSS): abdominal discomfort, bloating, or mild weight gain. - Headache. - Nausea. - Pelvic discomfort.

Serious or Rare Side Effects: - Severe OHSS: rapid weight gain, shortness of breath, ascites, or thromboembolic events. - Ovarian torsion. - Allergic reactions: rash, urticaria, or anaphylaxis. - Ectopic pregnancy risk. - Multiple pregnancy (twins or higher order).

What precautions apply to Follitropin Alfa (Genetical Recombination)?

Before initiating therapy, clinicians should evaluate individual risk factors and monitor response closely. - Patient selection: assess ovarian reserve and risk of OHSS. - Monitoring: perform serial ultrasound and estradiol measurements during stimulation. - Contraindications: avoid in patients with known hypersensitivity to follitropin alfa or its excipients. - Pregnancy: not indicated for use during an established pregnancy. - Hormone‑sensitive tumors: use with caution in patients with estrogen‑dependent cancers. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Follitropin Alfa (Genetical Recombination) interact with?

Follitropin alfa may interact with several agents that influence ovarian response. Major Interactions (Avoid): - GnRH agonists or antagonists: can alter ovarian response and may require dose adjustment. - Oral contraceptives: suppress endogenous FSH and can reduce efficacy if not discontinued appropriately. - Uncontrolled thyroid disease: may affect ovarian stimulation outcomes.

Moderate Interactions (Monitor Closely): - Clomiphene citrate: combined use can increase risk of OHSS; monitor closely. - Letrozole: may modify follicular development; estradiol levels should be observed. - Metformin or other insulin‑sensitising agents: can affect response in PCOS patients; monitor treatment effect.

Frequently asked questions

What is Ovaleap used for?+
Ovaleap is a recombinant follicle‑stimulating hormone used to stimulate the growth of ovarian follicles in women undergoing assisted reproductive techniques such as in‑vitro fertilisation, intra‑uterine insemination, or oocyte donation. It helps induce ovulation and supports the development of multiple eggs for retrieval.
How does follitropin alfa work?+
Follitropin alfa mimics the natural hormone FSH by binding to FSH receptors on ovarian granulosa cells. This activates intracellular signalling that promotes cell proliferation, estradiol production, and the maturation of ovarian follicles, ultimately leading to ovulation or the availability of mature oocytes for assisted reproduction.
What is the usual dose of Ovaleap?+
The dose of Ovaleap is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian reserve, treatment protocol, and response to monitoring. Dosing regimens can vary widely between different fertility programmes.
Is Ovaleap safe during pregnancy or breastfeeding?+
Ovaleap is intended for use before conception to stimulate follicular development. It is not indicated for use during an established pregnancy, and safety data for breastfeeding are limited. Women who become pregnant while on treatment should discontinue use and consult their healthcare provider.
How do I order Ovaleap from GNH USA?+
To request Ovaleap, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.
How does Ovaleap compare with other FSH products?+
Ovaleap is a recombinant FSH produced by genetic recombination, offering high purity and consistent activity compared with urinary‑derived FSH preparations. Clinical efficacy is comparable, but recombinant products like Ovaleap often have lower risk of immunogenic reactions and more predictable dosing.
What are the storage and handling requirements for Ovaleap?+
Ovaleap must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product has been kept at room temperature for more than 24 hours, discard it according to local regulations.
How is Ovaleap administered?+
Ovaleap is supplied as a sterile solution for subcutaneous injection. It is typically reconstituted with the provided diluent and administered using a fine‑gauge needle into the abdomen or thigh, following the dosing schedule prescribed by the treating fertility specialist.
What are the most serious risks associated with Ovaleap?+
The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, fluid accumulation, and thromboembolic events, as well as ovarian torsion, multiple pregnancy, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these complications.
Who should not use Ovaleap?+
Ovaleap should not be used in individuals with known hypersensitivity to follitropin alfa or any excipients, in patients with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent tumors, or in women who are already pregnant. Contra‑indications are assessed by the prescribing clinician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Follitropin Alfa (Genetical Recombination)
Route
Subcutaneous Use
Manufacturer
Theramex Ireland Limited
Origin
EU

Related products

Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU
Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU
Ovaleap

Ovaleap

Follitropin Alfa (Genetical Recombination)

Theramex Ireland Limited
EU